SAN FRANCISCO, Dec. 2, 2019 (GENENGNEWS) – Machine learning, says Cofactor Genomics, moves RNA-seq to RNA models, enables multidimensional biomarkers.
SAN FRANCISCO, Nov. 4, 2019 (FIERCEPHARMA) – Are more drugs really the answer to unlocking precision medicine? New focus that prioritizes patient profiling is likely to have major impact.
Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform
— Announces “Functional to FFPE” Early-Access Grant Program — San Francisco — November 6, 2019 (REPORTABLE) — Cofactor Genomics, leaders in RNA-based technologies and [...]
SAN FRANCISCO, Oct. 10, 2019 (CIOREVIEW) – Drug developers and clinicians are looking for a biomarker that can capture more of a patient’s immunological profile, their response to [...]
San Francisco, September 27, 2019 (REPORTABLE) — Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of [...]
Steven Daniel joins Cofactor Genomics as Vice President of Business Development — Leading Cofactor’s commercial efforts to grow the Predictive Immune Modeling market — San [...]
Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery
Cofactor Joins FNIH Biomarkers Consortium to Add Predictive Immune Modeling Expertise as New Resource for Multidimensional Biomarker Discovery — Contributing to both the Cancer and [...]
SAN FRANCISCO, Apr. 4, 2019 (FORBESBOOKS RADIO) -Dave Messina is COO of Cofactor Genomics; their multidimensional biomarker tools use RNA to enable doctors, drug developers and researchers to [...]
SAN FRANCISCO, Apr. 2, 2019 (CLINICAL OMICS) – Jarret Glasscock is the founder and CEO of Cofactor Genomics, a diagnostics company leveraging the power of RNA and Predictive Immune Modeling [...]